Jeni Lee
Partner @ Pivotal bioVenture Partners
San Francisco Bay Area, United States
Jeni Lee is a Series A investor at Pivotal bioVenture Partners in San Francisco Bay Area focused on Biotechnology and Health Care. Jeni Lee is the Board Member of Mosanna Therapeutics. She attended the University of California.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Jeni Lee invests in
Stages Jeni Lee invests in
Countries Jeni Lee invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (100%)
- Health Care 2 (67%)
- Therapeutics 2 (67%)
- Medical 1 (33%)
- Life Science 1 (33%)
Country
- United States 2 (67%)
- Switzerland 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Addition Therapeutics
|
Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovativemethods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies. | $100M / Series A / Dec 17, 2025 | |
Mosanna Therapeutics
|
Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. | $80M / Series A / Jun 09, 2025 | |
DermBiont
|
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes(fungi, bacteria, viruses, etc.). The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California. | $28M / Series A / Dec 21, 2021 |
Co-Investors
Pivotal bioVenture Partners is a $300 million life sciences venture capital fund established in 2017. They invest in privately held North American and European companies focused on innovative therapeutic products and platforms to address major unmet medical needs. They invest at all stages in a company’s evolution, from company creation through midand late stage clinical development. Their team brings diverse experience in venture capital, company building, and drug discovery and development to the table in working with entrepreneurs to advance their businesses.
Pivotal bioVenture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ash Khanna
Partner, Board Member HotSpot Tx, Bolt Bio, Fountain Tx and Evommune
|
|||
Heather Preston
Managing Partner
|
|||
|
Jeni Lee
Partner
|
|||
Robert Hopfner
Managing Partner
|
|||
|
Vincent Cheung
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jeni Lee invest in?
Jeni Lee invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jeni Lee?
Public channels for Jeni Lee include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jeni Lee last invest?
The most recent investment recorded for Jeni Lee closed in Dec 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
